IPO
News/ News/ Sales and Marketing
Oxford Nanopore makes stellar debut on UK stock market
Phil Taylor
financing, Gene Sequencing, genomics, IPO, Oxford Nanopore, UK biotech
0 Comment
Ambrx tries another IPO as it chases down HER2 rivals
Phil Taylor
Ambrx Biopharma, antibody-drug conjugate, AstraZeneca, Enhertu, financing, her2, IPO, Kadcyla, Roche
0 Comment
R&D/ Views & Analysis/ Views and analysis
Arecor heads for London Stock Exchange with drug reformulation strategy
Centessa plans $100m IPO to fund R&D and potential acquisitions
Richard Staines
cancer, Centessa, IPO, R&D, rare disease
0 Comment
Cancer Research UK spinout Achilles raises $175.5m in IPO
Phil Taylor
Achilles Therapeutics, Biotech, cell therapy, immuno-oncology, IPO, Oncology, UK
0 Comment
Protein misfolding specialist Gain nets $40m from IPO
Phil Taylor
computational, digital, drug discovery, Gain Therapeutics, IPO, Protein Misfolding, rare disease
0 Comment
Rubius launches $200m IPO to fund red blood cell therapies
Richard Staines
acute myeloid leukaemia, cancer, immunology, IPO, solid tumours
0 Comment
UK biotech investment at record levels amid COVID-19
Phil Taylor
financing, investment, IPO, UK, UK biotech, venture capital
0 Comment